Dasatinib + Quercetin is a senolytic combination therapy designed to selectively induce apoptosis (programmed cell death) in senescent cells. These 'zombie' cells accumulate with age, secreting a cocktail of inflammatory proteins (the SASP) that damage surrounding tissues and contribute to numerous age-related diseases. By clearing these cells, D+Q aims to reduce systemic inflammation, improve tissue function, and potentially delay, prevent, or alleviate age-related conditions.
Verdict
A potent but high-risk senolytic requiring strict medical guidance.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$500 - $2500
Protocol
- Intermittent dosing, such as Dasatinib 100mg and Quercetin 1000-1250mg daily for 2-3 consecutive days, repeated monthly or quarterly.
Flags
- Requires a prescription and close medical supervision.
- Dasatinib is a chemotherapy drug with numerous potential side effects, including fatigue, fluid retention, and myelosuppression.
- Potential for drug interactions, especially with CYP3A4 inhibitors/inducers (e.g., grapefruit juice).
- Long-term safety of intermittent use for healthspan is not yet established.